The UNC Blood Research Center (BRC) was established to promote interdisciplinary research in non-malignant blood disorders across UNC. It will seek to advance the work in the following specific areas.
One in four of the US population will succumb to a terminal thrombotic event, such as: myocardial infarction, stroke, or venous thromboembolism.
Basic science discoveries have paved the way towards better prophylactic and therapeutic approaches to thrombosis. However, a better understanding of the mechanisms underlying thrombosis and prevention without any risk of bleeding remains an unmet need. The BRC seeks to investigate potential approaches to both aims.
UNC is a world leader in hemophilia, from the development and administration of the first coagulation factor VIII concentrate to the role of the Chapel Hill dog colonies of the Francis Owen Blood Research Center in the pre-clinical testing of protein and gene therapies. The BRC aims to address the broad challenges that remain in numerous other inherited and acquired bleeding disorders.
Sickle cell disease affects approximately 100,000 Americans but accounts for an estimated 300,000 births worldwide every year, primarily in sub-Saharan Africa and the Indian sub-continent.
Compared to many other areas of medicine, the development of impactful therapies in sickle cell disease remains inadequate. We will continue to expand our research efforts to this under-served patient population into the future.
Tuesday 8:30 am
Tuesday 8:30 am
Wednesday 8:30 am
Friday 11:00 am
The symposium planned for 2024 will continue to focus on the latest findings in the field of hemostasis and thrombosis. In addition, we will feature a session to highlight the research of trainees attending the symposium.
Note: This activity has been approved for AMA PRA Category 1 Credit, 10.25 activity credits.
Please contact christine_hill@med.unc.edu with any questions.
Learn more about the symposium
4 days ago
Steven Grover, PhD was invited to present on the role of C1 inhibitor in venous thrombosis at the inaugural Immunothrombosis Symposium held at the Center for Advanced Studies of Ludwig Maximilians Universität in Munich. The two day symposium, hosted by Drs Konstantin Stark and Leo Nicolai, brought together researchers with an interest in immunothrombotic pathologies to …
2 weeks ago
Drs. Mackman and Hisada published an invited review article entitled “Mechanisms of cancer-associated thrombosis” in Research and Practice in Thrombosis and Haemostasis. In the review, they described 4 pathways of cancer-associated thrombosis including tissue factor-positive extracellular vesicles, podoplanin, neutrophil extracellular traps and plasminogen activator inhibitor-1. This review article is based on a State-of-the-Art lecture presented …
2 weeks ago
Erica Sparkenbaugh, PhD was awarded a one-year Stage 1 SBIR grant from NHLBI (HL169107-01) titled Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease. She is a subcontract on the grant with Chris Dockendorff at Function Therapeutics as PI.